Comparison of PET/MRI with multiparametric MRI in diagnosis of primary prostate cancer: A meta-analysis

2019 ◽  
Vol 113 ◽  
pp. 225-231 ◽  
Author(s):  
Mou Li ◽  
Zixing Huang ◽  
Haopeng Yu ◽  
Yi Wang ◽  
Yongchang Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Multiparametric Mri ◽  
Primary Prostate Cancer

scholarly journals Transcriptional landscape of PTEN loss in primary prostate cancer

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Eddie Luidy Imada ◽  
Diego Fernando Sanchez ◽  
Wikum Dinalankara ◽  
Thiago Vidotto ◽  
Ericka M. Ebot ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Pten Loss ◽  
Primary Prostate Cancer ◽  
Expression Atlas ◽  
Transcriptomic Signature ◽  
Transcriptional Changes ◽  
New Biomarkers ◽  
Adaptive Immune Systems ◽  
Transcriptional Landscape

Abstract Background PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. However, the transcriptional changes associated with PTEN loss in PCa have not been described in detail. In this study, we highlight the transcriptional changes associated with PTEN loss in PCa. Methods Using a meta-analysis approach, we leveraged two large PCa cohorts with experimentally validated PTEN and ERG status by Immunohistochemistry (IHC), to derive a transcriptomic signature of PTEN loss, while also accounting for potential confounders due to ERG rearrangements. This signature was expanded to lncRNAs using the TCGA quantifications from the FC-R2 expression atlas. Results The signatures indicate a strong activation of both innate and adaptive immune systems upon PTEN loss, as well as an expected activation of cell-cycle genes. Moreover, we made use of our recently developed FC-R2 expression atlas to expand this signature to include many non-coding RNAs recently annotated by the FANTOM consortium. Highlighting potential novel lncRNAs associated with PTEN loss and PCa progression. Conclusion We created a PCa specific signature of the transcriptional landscape of PTEN loss that comprises both the coding and an extensive non-coding counterpart, highlighting potential new players in PCa progression. We also show that contrary to what is observed in other cancers, PTEN loss in PCa leads to increased activation of the immune system. These findings can help the development of new biomarkers and help guide therapy choices.

Abbreviated Biparametric Versus Standard Multiparametric MRI for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 212 (2) ◽  
pp. 357-365 ◽  
Author(s):  
Zhen Kang ◽  
Xiangde Min ◽  
Jeffrey Weinreb ◽  
Qiubai Li ◽  
Zhaoyan Feng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Multiparametric Mri

scholarly journals Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e052277
Author(s):  
Yi Zhao ◽  
Naomi Morka ◽  
Benjamin Scott S Simpson ◽  
Alex Freeman ◽  
Alex Kirkham ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Positron Emission Tomography ◽  
Meta Analysis ◽  
Multiparametric Mri ◽  
Emission Tomography ◽  
Prostate Specific Membrane Antigen ◽  
Positron Emission ◽  
Psma Pet ◽  
Specific Membrane

IntroductionThe introduction of multiparametric MRI (mpMRI) has improved almost every aspect of the prostate cancer diagnostic pathway. However, the novel imaging technique, prostate-specific membrane antigen positron emission tomography (PSMA PET) may have demonstrable accuracy in detecting and staging prostate cancer. Here, we describe a protocol for a systematic review and meta-analysis comparing mpMRI to PSMA PET for the diagnosis of suspected prostate cancer.Methods and analysisA systematic search of MEDLINE, EMBASE, PubMed and Cochrane databases will be conducted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed for screening, data extraction, statistical analysis and reporting. Included papers will be full-text articles providing original data, written in English articles and comparing the use of PSMA PET with mpMRI in the diagnosis of prostate cancer. All studies published between July 1977 and March 2021 will be eligible for inclusion. Study bias and quality will be assessed using Quadas-2 score. To ensure the quality of the reporting of studies, this protocol is written following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist.Ethics and disseminationEthical approval will not be required for this systematic review. Findings will be disseminated through peer-reviewed publications and presentations at both national and international conferences.PROSPERO registration numberCRD42021239296.

Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis

2014 ◽  
Vol 202 (2) ◽  
pp. 343-351 ◽  
Author(s):  
Maarten de Rooij ◽  
Esther H. J. Hamoen ◽  
Jurgen J. Fütterer ◽  
Jelle O. Barentsz ◽  
Maroeska M. Rovers
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Meta Analysis ◽  
Multiparametric Mri ◽  
Prostate Cancer Detection

Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?

2019 ◽  
Vol 37 (3) ◽  
pp. 181.e1-181.e6 ◽  
Author(s):  
Bernard H.E. Jansen ◽  
Jakko A. Nieuwenhuijzen ◽  
Daniela E. Oprea-Lager ◽  
Marit J. Yska ◽  
Anne P. Lont ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Staging ◽  
Multiparametric Mri ◽  
Local Tumor ◽  
Primary Prostate Cancer

scholarly journals Transcriptional landscape of PTEN loss in primary prostate cancer

2020 ◽  
Author(s):  
Eddie Luidy Imada ◽  
Diego Fernando Sanchez ◽  
Wikum Dinalankara ◽  
Thiago Vidotto ◽  
Ericka M Ebot ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Pten Loss ◽  
Adaptive Immune ◽  
Primary Prostate Cancer ◽  
Expression Atlas ◽  
Transcriptomic Signature ◽  
Transcriptional Changes ◽  
Adaptive Immune Systems ◽  
Transcriptional Landscape

ABSTRACTPTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. However, the transcriptional changes associated with PTEN loss in PCa have not been described in detail. Here, we applied a meta-analysis approach, leveraging two large PCa cohorts with experimentally validated PTEN and ERG status, to derive a transcriptomic signature of PTEN loss, while also accounting for potential confounders due to ERG rearrangements. Strikingly, the signature indicates a strong activation of both innate and adaptive immune systems upon PTEN loss, as well as an expected activation of cell-cycle genes. Moreover, we made use of our recently developed FC-R2 expression atlas to expand this signature to include many non-coding RNAs recently annotated by the FANTOM consortium. With this resource, we analyzed the TCGA-PRAD cohort, creating a comprehensive transcriptomic landscape of PTEN loss in PCa that comprises both the coding and an extensive non-coding counterpart.

Sign in / Sign up

Export Citation Format

Share Document